Novel score for prediction of malignant bile duct obstruction based on biochemical and clinical markers.

Abstract:

BACKGROUND:Early differentiation of malignant from benign bile duct obstruction is of utmost importance. AIM:To identify biochemical and clinical predictors for malignancy in patients with bile duct obstruction, and establish a predictive model by combining pre-treatment patient characteristics. A web-based application was developed for easy assessment of malignant bile duct probability (www.pmal-score.org). METHODS:One thousand hundred and thirty-five patients [median age 66 (52-75) years, 53% male] with bile duct obstruction of various aetiologies were retrospectively evaluated at our tertiary referral centre. Multivariate logistic regression analysis identified factors as independently significant for malignant bile duct obstruction. A predictive risk score was established using ROC analysis and applied to an external validation cohort of 101 patients. RESULTS:Three hundred and ninety-four patients had malignant bile duct obstruction proven by surgery, while in 741 patients benign obstruction was observed. Multivariate analysis identified various clinical factors to be predictive for malignancy. On the basis of eight predictors, a risk score for malignancy was developed [X = 0.025 * [age] + 1.239 * [1 if weight loss, otherwise 0] - 0.235 * [1 if pain, otherwise 0] + 0.649 * [1 if diabetes, otherwise 0] + 0.896 * [1 if jaundice, otherwise 0] + 0.109 * [bilirubin] + 0.0007 * [γ-GT] + 0.0003 * [AP] - 4.374]: A significant correlation between the predicted malignancy and the actual malignancy was found by ROC (AUC: 0.862; 95% CI 0.838-0.886, P < 0.0001). CONCLUSIONS:This predictive risk score estimates the risk of malignancy in patients with bile duct obstruction, and it seems to be very accurate. A better prediction enables both earlier diagnosis of malignant obstructive disease and improved management of patients with bile duct obstruction, which may result in reduced morbidity and mortality.

journal_name

Aliment Pharmacol Ther

authors

Meister T,Uphoff MA,Heinecke A,Domagk D,Kunsch S,Lindhorst A,Ellenrieder V,Heinzow HS

doi

10.1111/apt.13152

subject

Has Abstract

pub_date

2015-05-01 00:00:00

pages

877-87

issue

9

eissn

0269-2813

issn

1365-2036

journal_volume

41

pub_type

杂志文章
  • Influence of tegaserod on proximal gastric tone and on the perception of gastric distension.

    abstract:BACKGROUND:Tegaserod, a 5-hydroxytryptamine-4 receptor agonist, enhances gastric emptying, but its effects on proximal stomach function have not been studied. AIM:To study the effect of tegaserod on gastric compliance, accommodation and perception of distension in humans. METHODS:Nineteen healthy volunteers (10 femal...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.2003.01775.x

    authors: Tack J,Vos R,Janssens J,Salter J,Jauffret S,Vandeplassche G

    更新日期:2003-11-15 00:00:00

  • Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection.

    abstract:BACKGROUND:One-week low-dose proton pump inhibitor-based triple therapies have usually proved to be effective treatments for Helicobacter pylori infection. AIM:To investigate the eradication efficacy, safety profile and patient compliance of two triple therapies containing a standard dose of rabeprazole and a new fluo...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1046/j.1365-2036.2000.00846.x

    authors: Cammarota G,Cianci R,Cannizzaro O,Cuoco L,Pirozzi G,Gasbarrini A,Armuzzi A,Zocco MA,Santarelli L,Arancio F,Gasbarrini G

    更新日期:2000-10-01 00:00:00

  • Prescription of nonselective NSAIDs, coxibs and gastroprotective agents in the era of rofecoxib withdrawal - a 617,400-patient study.

    abstract:BACKGROUND:Gastroprotective strategies are recommended for nonsteroidal anti-inflammatory drug (NSAID) users at risk of upper gastrointestinal (UGI) complications. AIM:To compare the use of gastroprotective strategies in NSAID users in three countries, and the subsequent impact of rofecoxib withdrawal. METHODS:We con...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12028

    authors: Valkhoff VE,van Soest EM,Masclee GM,de Bie S,Mazzaglia G,Molokhia M,Kuipers EJ,Sturkenboom MC

    更新日期:2012-10-01 00:00:00

  • The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens.

    abstract:BACKGROUND:Guidelines recommend withholding sofosbuvir (SOF) in patients with an estimated glomerular filtration rate (eGFR) of less than 30 mL/min. AIM:To assess the risk of acute kidney injury (AKI) in patients with no renal contraindications for SOF-based treatment. METHODS:This multicenter retrospective observati...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/apt.14117

    authors: Maan R,Al Marzooqi SH,Klair JS,Karkada J,Cerocchi O,Kowgier M,Harrell SM,Rhodes KD,Janssen HLA,Feld JJ,Duarte-Rojo A

    更新日期:2017-07-01 00:00:00

  • An analysis of the placebo effect in Crohn's disease over time.

    abstract:BACKGROUND:Randomized, placebo controlled trials are used to assess the efficacy of therapies for Crohn's disease. The placebo response and remission rates vary among studies. AIM:To analyse how the placebo response and remission rates in Crohn's trials have changed over time in the era of parenteral biologic therapie...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2009.04125.x

    authors: Gallahan WC,Case D,Bloomfeld RS

    更新日期:2010-01-01 00:00:00

  • The effect of rebamipide on the expression of proinflammatory mediators and apoptosis in human neutrophils by Helicobacter pylori water-soluble surface proteins.

    abstract:BACKGROUND:Helicobacter pylori infection elicits persistent neutrophil infiltration in gastric mucosa. The expression of cyclooxygenase (COX)-2 and inhibition of apoptosis in the neutrophils could contribute to the pathogenesis of H. pylori infection. Rebamipide, a mucosal protective and ulcer-healing drug, has been kn...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.18.s1.1.x

    authors: Kim JS,Kim JM,Jung HC,Song IS

    更新日期:2003-07-01 00:00:00

  • Review article: the epidemiology and prevention of gastric cancer.

    abstract:BACKGROUND:Gastric cancer can be divided into cardia and noncardia gastric adenocarcinoma (NCGA). Non cardia gastric cancer is a disease that has declined in global incidence but has remained as an extremely lethal cancer. AIM:To review recent advances in epidemiology and strategies in prevention of non cardia gastric...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.12814

    authors: Fock KM

    更新日期:2014-08-01 00:00:00

  • Octreotide in the prevention of pancreatic injury associated with endoscopic cholangiopancreatography.

    abstract:BACKGROUND:Data on whether long-acting somatostatin analogue octreotide causes or prevents pancreatic injury following endoscopic retrograde cholangiopancreatography (ERCP) are controversial. AIM:This multicentre, prospective trial studied the effect of octreotide on pancreatic injury in a large unselected group of pa...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1046/j.1365-2036.1998.00414.x

    authors: Tulassay Z,Döbrönte Z,Prónai L,Zágoni T,Juhász L

    更新日期:1998-11-01 00:00:00

  • Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis--a randomized controlled, cross-over trial.

    abstract:BACKGROUND:Gastro-oesophageal reflux disease (GERD) is an important problem in systemic sclerosis due to impaired salivation and oesophageal function. AIM:To determine the efficacy of adding ranitidine at bedtime to control nocturnal acid breakthrough (NAB) and GERD in patients with systemic sclerosis already prescrib...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2007.03469.x

    authors: Janiak P,Thumshirn M,Menne D,Fox M,Halim S,Fried M,Brühlmann P,Distler O,Schwizer W

    更新日期:2007-11-01 00:00:00

  • Overlap of gastro-oesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population.

    abstract:BACKGROUND:Gastro-oesophageal reflux disease (GERD) and irritable bowel syndrome may occur more often than expected by chance, but little community data exists and risk factors are unknown. AIM:To determine prevalence and risk factors for overlap of GERD and irritable bowel disease. METHODS:Population-based, cross-se...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2036.2007.03366.x

    authors: Jung HK,Halder S,McNally M,Locke GR 3rd,Schleck CD,Zinsmeister AR,Talley NJ

    更新日期:2007-08-01 00:00:00

  • Review article: 'true' re-infection of Helicobacter pylori after successful eradication--worldwide annual rates, risk factors and clinical implications.

    abstract:BACKGROUND:The incidence of 'true' re-infection with Helicobacter pylori after successful eradication remains uncertain. AIM:To determine the worldwide rates, risk factors and clinical implications of 'true' re-infection of Helicobacter pylori. 'True' re-infection of H. pylori is defined as the situation where tests f...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2008.03873.x

    authors: Zhang YY,Xia HH,Zhuang ZH,Zhong J

    更新日期:2009-01-01 00:00:00

  • Personal view: adequate relief as a primary endpoint in irritable bowel syndrome.

    abstract::The success of a clinical trial is judged by achieving statistical and clinical significance on the primary endpoint. This is particularly relevant in those trials that are initiated to achieve regulatory approval of a new therapeutic agent. Selection of an endpoint for which statistical significance will be too diffi...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2006.02839.x

    authors: Mangel AW

    更新日期:2006-04-01 00:00:00

  • Review article: historic changes of Helicobacter pylori-associated diseases.

    abstract:BACKGROUND:The long-term time trends of multiple gastrointestinal diseases are characterised by a striking rise and fall. These temporal changes provide important clues about disease aetiology. AIM:To highlight the importance of Helicobacter pylori infection in shaping the temporal trends of many common gastrointestin...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 历史文章,杂志文章,评审

    doi:10.1111/apt.12380

    authors: Sonnenberg A

    更新日期:2013-08-01 00:00:00

  • Effects of interferon-beta on plasma lipid and lipoprotein composition and post-heparin lipase activities in patients with chronic hepatitis C.

    abstract:BACKGROUND:Interferon therapy has been shown to induce lipid abnormalities. AIM:We assessed the effects of interferon-beta on the lipoprotein profile and post-heparin lipase activities in 26 normolipaemic patients with chronic hepatitis C. METHODS:Interferon-beta was administered subcutaneously at doses of 6 x 106 U ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1046/j.1365-2036.2000.00792.x

    authors: Andrade RJ,García-Escaño MD,Valdivielso P,Alcántara R,Sánchez-Chaparro MA,González-Santos P

    更新日期:2000-07-01 00:00:00

  • Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort.

    abstract:BACKGROUND:Ustekinumab is a monoclonal antibody targeting interleukins-12 and -23, with efficacy in Crohn's disease (CD) demonstrated in clinical trials. AIM:To assess the real-world clinical, endoscopic and radiographic response and remission outcomes achieved with ustekinumab in medically-refractory CD. METHODS:A r...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/apt.14016

    authors: Ma C,Fedorak RN,Kaplan GG,Dieleman LA,Devlin SM,Stern N,Kroeker KI,Seow CH,Leung Y,Novak KL,Halloran BP,Huang VW,Wong K,Blustein PK,Ghosh S,Panaccione R

    更新日期:2017-05-01 00:00:00

  • Review article: methotrexate in gastroenterology--dangerous villain or simply misunderstood?

    abstract::Methotrexate has a place in the treatment of an increasing number of diseases. Its emerging role in the treatment of primary biliary cirrhosis and inflammatory bowel disease still requires further evaluation. Its toxicity profile is wide and is affected by a variety of factors. Hepatotoxicity from long-term use in pat...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.1996.70244000.x

    authors: Tang H,Neuberger J

    更新日期:1996-12-01 00:00:00

  • The impact of direct-acting anti-virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States.

    abstract:BACKGROUND:The hepatitis C virus (HCV) care cascade has changed dramatically following the introduction of direct-acting anti-virals (DAAs). Up-to-date estimates of the cascade are needed to monitor progress, identify key gaps and inform policy. AIM:To estimate the current and future HCV care cascade in the United Sta...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.15291

    authors: Chhatwal J,Chen Q,Bethea ED,Hur C,Spaulding AC,Kanwal F

    更新日期:2019-07-01 00:00:00

  • Mucosal penetration and clearance of gluten and milk antigens in eosinophilic oesophagitis.

    abstract:BACKGROUND:The Th2 allergic pathway in eosinophilic oesophagitis (EoE) responds to food antigen exposure. AIM:To compare the presence and temporal pattern of food antigen penetration in oesophageal mucosa in active and inactive EoE and controls METHODS: Thirty-two patients with EoE (20 active) and 10 controls were ask...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.16180

    authors: Ravi A,Marietta EV,Alexander JA,Peterson K,Lavey C,Geno DM,Murray JA,Katzka DA

    更新日期:2021-02-01 00:00:00

  • Rat CXC chemokine GRO/CINC-1 paradoxically stimulates the growth of gastric epithelial cells.

    abstract:BACKGROUND:CXC chemokines such as interleukin (IL)-8 are neutrophil chemoattractants, the levels of which increase in Helicobacter pylori-infected gastric mucosa. Many investigators have focused on the chemotactic aspects of IL-8: however, CXC chemokines are also reported to have angiogenic activity and to serve as rem...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2000.014s1094.x

    authors: Suzuki H,Mori M,Seto K,Shibata F,Nagahashi S,Kawaguchi C,Suzuki M,Matsui H,Watanabe K,Miura S,Ishii H

    更新日期:2000-04-01 00:00:00

  • Helicobacter-negative gastritis: polymerase chain reaction for Helicobacter DNA is a valuable tool to elucidate the diagnosis.

    abstract:BACKGROUND:Helicobacter-negative gastritis has been increasingly reported. Molecular techniques as the polymerase chain reaction (PCR) may detect bacterial DNA in histologically negative gastritis. AIM:To evaluate of Helicobacter PCR in gastric biopsies for the daily diagnostics of Helicobacter-negative gastritis. ME...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13564

    authors: Kiss S,Zsikla V,Frank A,Willi N,Cathomas G

    更新日期:2016-04-01 00:00:00

  • The effects of low doses of ranitidine on intragastric acidity in healthy men.

    abstract:BACKGROUND:H2-receptor antagonists are becoming widely available as over-the-counter medications for the treatment of heartburn and excess gastric acidity. AIM:To determine the effects of single low doses of ranitidine on intragastric acidity. METHODS:Intragastric pH was measured for 9 h after lunch in five studies i...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.1998.00307.x

    authors: Wyeth JW,Pounder RE,Sercombe JC,Snell CC

    更新日期:1998-03-01 00:00:00

  • Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides.

    abstract:BACKGROUND:The treatment of HBeAg-negative chronic hepatitis B (CHB) is considered to be open-ended, with no guidelines for treatment cessation. AIM:To evaluate biochemical and virological relapse requiring retreatment in noncirrhotic HBeAg-negative CHB in patients who stopped treatment following a period of prolonged...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12908

    authors: Patwardhan VR,Sengupta N,Bonder A,Lau D,Afdhal NH

    更新日期:2014-10-01 00:00:00

  • Review article: transcriptional events controlling the terminal differentiation of intestinal endocrine cells.

    abstract::Secretin-producing enteroendocrine cells arise from a multipotential endocrine progenitor in the crypts of the small intestine. As these cells migrate up the crypt-villus axis, they produce secretin and stop dividing as they terminally differentiate and die. Transcription of the secretin gene is controlled by a comple...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2000.014s1170.x

    authors: Mutoh H,Ratineau C,Ray S,Leiter AB

    更新日期:2000-04-01 00:00:00

  • A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis.

    abstract:BACKGROUND:Proton pump inhibitors are effective for the healing of oesophagitis. Standard doses of omeprazole, lansoprazole or pantoprazole are sufficient for healing in mild to moderate cases of oesophagitis. AIM:To compare the efficacy of double the standard doses of omeprazole, lansoprazole or pantoprazole for main...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.1998.00278.x

    authors: Jaspersen D,Diehl KL,Schoeppner H,Geyer P,Martens E

    更新日期:1998-01-01 00:00:00

  • Role of inducible nitric oxide synthase in dextran sulphate sodium-induced colitis.

    abstract:BACKGROUND:Different authors have postulated both toxic and protective effects for nitric oxide (NO) in the pathophysiology of active inflammation. AIM:To examine the role of NO, especially that produced by the inducible form of nitric oxide synthase (iNOS), by investigating the effects of NOS inhibitors and NO donors...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2000.014s1026.x

    authors: Yoshida Y,Iwai A,Itoh K,Tanaka M,Kato S,Hokari R,Miyahara T,Koyama H,Miura S,Kobayashi M

    更新日期:2000-04-01 00:00:00

  • Influence of the selective serotonin re-uptake inhibitor, paroxetine, on gastric sensorimotor function in humans.

    abstract:BACKGROUND:The role of 5-hydroxytryptamine in the control of gastric fundus tone in humans is still unknown. Selective 5-hydroxytryptamine re-uptake inhibitors act both centrally and peripherally to enhance the availability of physiologically released 5-hydroxytryptamine. AIM:To study the influence of a selective 5-hy...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.2003.01469.x

    authors: Tack J,Broekaert D,Coulie B,Fischler B,Janssens J

    更新日期:2003-02-15 00:00:00

  • Clinical response after transjugular intrahepatic portosystemic stent shunt insertion for refractory ascites in cirrhosis.

    abstract:BACKGROUND:Transjugular intrahepatic portosystemic stent shunts (TIPSS) have been used successfully to reduce portal pressure in the context of variceal haemorrhage. Recent interest has focused on the possible use of TIPSS to manage refractory ascites. AIM:To study the effect of TIPSS insertion in 18 patients with ref...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.1996.60202000.x

    authors: Forrest EH,Stanley AJ,Redhead DN,McGilchrist AJ,Hayes PC

    更新日期:1996-10-01 00:00:00

  • Variants of OCTN1-2 cation transporter genes are associated with both Crohn's disease and ulcerative colitis.

    abstract:BACKGROUND:Two variants in the organic cation transporter gene cluster have been recently reported to confer susceptibility to Crohn's disease (CD). AIM:To investigate these variants in CD and ulcerative colitis (UC), and their interaction with CARD15 gene and correlation to clinical subphenotypes. METHODS:Case-contr...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.02780.x

    authors: Palmieri O,Latiano A,Valvano R,D'Incà R,Vecchi M,Sturniolo GC,Saibeni S,Peyvandi F,Bossa F,Zagaria C,Andriulli A,Devoto M,Annese V

    更新日期:2006-02-15 00:00:00

  • Psychiatric co-morbidity is associated with increased risk of surgery in Crohn's disease.

    abstract:BACKGROUND:Psychiatric co-morbidity, in particular major depression and anxiety, is common in patients with Crohn's disease (CD) and ulcerative colitis (UC). Prior studies examining this may be confounded by the co-existence of functional bowel symptoms. Limited data exist examining an association between depression or...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12195

    authors: Ananthakrishnan AN,Gainer VS,Perez RG,Cai T,Cheng SC,Savova G,Chen P,Szolovits P,Xia Z,De Jager PL,Shaw SY,Churchill S,Karlson EW,Kohane I,Perlis RH,Plenge RM,Murphy SN,Liao KP

    更新日期:2013-02-01 00:00:00

  • Nitrofurantoin quadruple therapy for Helicobacter pylori infection: effect of metronidazole resistance.

    abstract:BACKGROUND:Antibiotic resistance has increasingly been recognized as the major cause of treatment failure for Helicobacter pylori infection. New therapies for patients with metronidazole- or clarithromycin-resistant H. pylori are needed. AIM:To investigate the role of nitrofurantoin quadruple therapy for the treatment...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1046/j.1365-2036.2001.00945.x

    authors: Graham DY,Saeed MA,Hoffman J,El-Zimaity HM,Kwon DH,Osato MS

    更新日期:2001-04-01 00:00:00